A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy

RecruitingOBSERVATIONAL
Enrollment

120

Participants

Timeline

Start Date

January 17, 2024

Primary Completion Date

April 2, 2026

Study Completion Date

April 2, 2026

Conditions
Hemophilia B
Interventions
OTHER

Non-Interventional

No study treatment will be administered in this study.

Trial Locations (22)

19104

RECRUITING

Children's Hospital of Philadelphia (CHOP), Philadelphia

20057

RECRUITING

Georgetown University Medical Center, Washington D.C.

20246

RECRUITING

University Hospital Hamburg Eppendorf, Hamburg

32610

RECRUITING

University of Florida, Gainesville

37212

RECRUITING

Vanderbilt University Medical Center, Nashville

43205

RECRUITING

Nationwide Children's Hospital, Columbus

44106

RECRUITING

University Hospitals Cleveland Medical Center, Cleveland

46260

RECRUITING

Indiana Hemophilia and Thrombosis Center, Indianapolis

48109

RECRUITING

University of Michigan, Ann Arbor

60590

RECRUITING

Klinikum der Johann Wolfgang Goethe-Universitaet Frankfurt, Frankfurt

60612

RECRUITING

Rush University Medical Center, Chicago

77030

RECRUITING

University of Texas Health Science Center at Houston, Houston

80045

RECRUITING

University of Colorado Hemophilia and Thrombosis Center, Aurora

90007

COMPLETED

Orthopaedic Hemophilia Treatment Center, Los Angeles

93053

RECRUITING

University Hospital of Regensburg, Regensburg

06520

RECRUITING

Yale HTC, New Haven

L8N 3Z5

RECRUITING

McMaster University Medical Centre - Hamilton Health Sciences, Hamilton

H4A 3J1

RECRUITING

Mcgill University Health Center (MUHC), Montreal

SO16 6YD

RECRUITING

Southampton General Hospital, Southampton

G31 2ER

RECRUITING

Glasgow Royal Infirmary - Clinical Research Facility, Glasgow

E1 1FR

RECRUITING

Barts Health NHS Trust, Royal London Hospital, London

SE1 7EH

RECRUITING

St. Thomas' Hospital, London

All Listed Sponsors
lead

Regeneron Pharmaceuticals

INDUSTRY